pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Dificid
drug
save

Dificid

Marketedupdated 3mo ago
by Cubist Pharmaceuticals LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval4 co-mentions · 2 sources
  • tagSmall Molecule2 co-mentions · 2 sources
  • drugFIDAXOMICIN2 co-mentions · 2 sources

all catalysts(2)

approval · 2
Jan 27, 2026
approval
7mo ago
FIDAXOMICIN — FDA approval
Dificid
→
Feb 2, 2026
approval
7mo ago
FIDAXOMICIN — FDA approval
Dificid
→

Trials studying Dificid

  • phase3Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicincompletedn=93
  • phase3A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)completedn=148
  • phase4Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)completedn=25
  • phase4A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Populationcompletedn=364
  • —Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)withdrawn

Patent cliff

source: FDA Orange Book
first barrier falls
Jan 24, 2027
159 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

  • Nov 28, 2034patentUS 9808530*PED
  • May 28, 2034formulationUS 9808530
  • Jan 31, 2028patentUS 7378508*PED1.5y
  • Jan 31, 2028patentUS 7378508*PED1.5y
  • Jan 31, 2028patentUS 7863249*PED1.5y
  • Jan 31, 2028patentUS 7863249*PED1.5y
  • Jan 31, 2028patentUS 8859510*PED1.5y
  • Jan 31, 2028patentUS 8859510*PED1.5y
  • Sep 4, 2027patentUS 7906489*PED1.0y
  • Sep 4, 2027patentUS 7906489*PED1.0y
  • Jul 31, 2027compositionUS 7378508347d
  • Jul 31, 2027compositionUS 7378508347d
  • Jul 31, 2027compositionUS 7863249347d
  • Jul 31, 2027formulationUS 7863249347d
  • Jul 31, 2027method-of-use (U-2741)US 8859510347d
  • Jul 31, 2027method-of-use (U-2741)US 8859510347d
  • Mar 4, 2027method-of-use (U-2741)US 7906489198d
  • Mar 4, 2027method-of-use (U-2741)US 7906489198d

FDA exclusivities (2)

  • Jan 24, 2027ODE-367Orphan Drug (7y)159d
  • Jan 24, 2027ODE-367Orphan Drug (7y)159d

News(0)

no news has mentioned this drug yet

brand
Dificid
generic
fidaxomicin
indication
Infectious Diarrhea
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 19m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?